Panthera moves back into recruiting and running commercial oncology clinical trials in the UK

Since announcing that it reopened its oncology clinical trials division earlier this year, Panthera Biopartners has been selected by two of the world’s largest pharma companies to run oncology trials at sites across the UK. Panthera previously had to close its Oncology division as the sites were located inside the four Rutherford Specialist Cancer clinics, which went into administration.
Since then, Panthera has expanded its existing clinical trial sites to recruit for immunotherapy and hormone therapy oncology trials and has recruited a broad team of specialist oncologists PIs.
Chris Dodd, Chief Commercial Officer at Panthera, commented “There is a great shortage of top quality oncology clinical trial sites with experienced oncology specialists across the world. The UK is particularly well placed to become a centre for running commercial oncology trials with top-quality PIs, a diverse population and experienced clinical trial sites. We were very successful in attracting oncology studies to the UK. With our clinics set up to run these trials and a team of world-class oncology specialists, we are well on our way to re-establishing Panthera as a major player in this area.”
Panthera, which has six dedicated clinical trial sites across the UK in Glasgow, York, Sheffield, Preston, Rochdale and Enfield, carries out clinical trials for pharma, biotechs and CROs across a broad range of therapy areas including vaccines, cardiovascular, general medicine, neurology, respiratory and rheumatology.